Reistone Biopharma
Currently we are looking for either partnership to develop the AD and/or UC or CD indications for phase 3 or out-license the global right excluding China market.
Paul Chen
Chief of StaffSanten Pharmaceutical
Santen Pharmaceutical Co., Ltd. (参天製薬株式会社), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.
We are looking for investment and licensing opportunites in the ophthalmology field.
Shanghai Pharma Holding
Dawei Jiang
Sr. BD ManagerShenzhen Beimei Pharmaceutical Co. Ltd.
Ivy Zhou
Head of Business DevelopmentSichuan Kelun-Biotech Biopharmaceutical Co., Ltd
Kelun-Biotech Biopharmaceutical is a subsidiary of Kelun Pharmaceutical Group established in 2016
Looking for antibody and samall molecular out-license and in-license
Chunlin Li
BD btlichl@kelun.comSimcere Pharmaceutical Group
We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”
Wayne Yin
BD DirectorSoligenix, Inc.
Dan Ring
Vice President, Business Development & Strategic PlanningSOTIO a.s.
Sotio is developing the next generation of potent immunotherapies for patients with cancer. The Company is building its pipeline of attractive oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Sotio’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.
Norbert Prenzel
Head of Business Development and LicensingVISEN Pharmaceutical
VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.